Ani Pharmaceuticals INC 8-K filings

ANI Pharmaceuticals finalized its acquisition of Alimera Sciences on September 16, 2024, including a contingent value rights agreement tied to future revenue targets.

ANI Pharmaceuticals has completed its acquisition of Alimera Sciences, significantly expanding its rare disease business and adding two key ophthalmology products.

ANI Pharmaceuticals successfully closes a $316.25 million convertible senior notes offering, including the full exercise of the initial purchasers' option to purchase additional notes.

ANI Pharmaceuticals has successfully priced a private offering of $275 million in convertible senior notes, increasing the offering size from the initially planned $250 million.

ANI Pharmaceuticals plans to raise $250 million through a private offering of convertible senior notes due in 2029 to repay existing debt and for general corporate purposes.

ANI Pharmaceuticals announced record second-quarter revenues, driven by its Rare Disease segment, and increased its full-year 2024 financial guidance.

ANI Pharmaceuticals will acquire Alimera Sciences for $5.50 per share in cash plus a contingent value right, aiming to bolster its rare disease business.

ANI Pharmaceuticals is experiencing significant growth, particularly in its Rare Disease segment, with strong financial performance and positive outlook for 2024.

ANI Pharmaceuticals held its 2024 Annual Meeting where stockholders approved the amended stock incentive plan and elected eight directors.

ANI Pharmaceuticals presented at the Capital One Securities event, emphasizing the significant growth of its rare disease business, particularly with Purified Cortrophin Gel.

ANI Pharmaceuticals announced record first quarter 2024 financial results, highlighted by significant growth in its Rare Disease segment and overall revenue.

ANI Pharmaceuticals showcases robust financial performance and strategic growth initiatives, particularly in its Rare Disease and Generics businesses.

ANI Pharmaceuticals showcases robust financial performance and growth prospects, particularly in its Rare Disease segment, during an investor presentation.

ANI Pharmaceuticals announced record full-year 2023 financial results driven by strong growth in its Rare Disease business, and provided an optimistic outlook for 2024.

ANI Pharmaceuticals has entered into an agreement to sell its former manufacturing facility in Oakville, Ontario for $19.2 million Canadian dollars, or approximately $14.2 million US dollars.

ANI Pharmaceuticals is experiencing significant growth, particularly in its Rare Disease segment, with strong financial results and increased guidance for 2023.